ImQuest assisted with HBV neutralization assays to support the the recent publication in npj Vaccines. See the abstract below:

Abstract

While several COVID-19 vaccines have been in use, more effective and durable vaccines are needed to combat the ongoing COVID-19 pandemic. Here, we report highly immunogenic self-assembling SARS-CoV-2 spike-HBsAg nanoparticles displaying a six-proline-stabilized WA1 (wild type, WT) spike S6P on a HBsAg core. These S6P-HBsAgs bound diverse domain-specific SARS-CoV-2 monoclonal antibodies. In mice with and without a HBV pre-vaccination, DNA immunization with S6P-HBsAgs elicited significantly more potent and durable neutralizing antibody (nAb) responses against diverse SARS-CoV-2 strains than that of soluble S2P or S6P, or full-length S2P with its coding sequence matching mRNA-1273. The nAb responses elicited by S6P-HBsAgs persisted substantially longer than by soluble S2P or S6P and appeared to be enhanced by HBsAg pre-exposure. These data show that genetic delivery of SARS-CoV-2 S6P-HBsAg nanoparticles can elicit greater and more durable nAb responses than non-nanoparticle forms of stabilized spike. Our findings highlight the potential of S6P-HBsAgs as next generation genetic vaccine candidates against SARS-CoV-2.

Liu et al.

Contact us to learn more about about our services for the testing of novel Hepatitis B virus therapeutic products. HBV stock virus are also available for purchase for use in in vitro and in vivo assays.

The post ImQuest Publication Highlight: HBV Neutralization Assays appeared first on ImQuest BioSciences.

ImQuest assisted with HIV resistance and characterization assays to support the the recent publication in ACS Infection Disease. See the abstract below:

Abstract

The HIV-1 infection epidemic remains a global health problem. Current antiretroviral treatments are effective in controlling the progression of a severe infection. However, the emergence of drug resistance requires an urgent identification of new treatment regimes. HIV-1 reverse transcriptase (RTs) has been a successful therapeutic target owing to its high specificity and potent antiviral properties; therefore, it has become an essential component of current HIV-1 standard treatments. This study identified a new HIV-1 RTs inhibitor (Compound #8) that is structurally unique and greatly effective against HIV-1 through chemical library screening and a medicinal chemistry program by analyzing the structure–activity relationship (SAR). Further analysis of molecular docking and mechanisms of action demonstrated that Compound #8 is a novel type of HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with a flexible binding mode. Therefore, it exhibits great therapeutic potential when combined with other existing HIV-1 drugs. Our current studies suggest that Compound #8 is a promising novel scaffold for the development of new HIV-1 treatments.

Kim et al.

Contact us to learn more about about our services for assessing viral barrier to resistance, and forcing the selection of resistant mutants to elucidate mechanism of action of novel antivirals.

The post ImQuest Publication Highlight: Viral Resistance Characterization and Selection appeared first on ImQuest BioSciences.

ImQuest assisted with HBV primary human hepatocyte assays to support the the recent publication in the Journal of Clinical Investigation (JCI). See the abstract below:

Abstract

Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or virus family, and the pathogen can readily evolve resistance. Host-targeted antivirals can overcome these limitations. The broad-spectrum activity achieved by host targeting can be especially useful in combating emerging viruses and for treatment of diseases caused by multiple viral pathogens, such as opportunistic agents in immunosuppressed patients. We have developed a family of compounds that modulate sirtuin 2, an NAD⁺-dependent deacylase, and now report the properties of a member of that family, FLS-359. Biochemical and x-ray structural studies show that the drug binds to sirtuin 2 and allosterically inhibits its deacetylase activity. FLS-359 inhibits the growth of RNA and DNA viruses, including members of the coronavirus, orthomyxovirus, flavivirus, hepadnavirus, and herpesvirus families. FLS-359 acts at multiple levels to antagonize cytomegalovirus replication in fibroblasts, causing modest reductions in viral RNAs and DNA, together with a much greater reduction in infectious progeny, and it exhibits antiviral activity in humanized mouse models of infection. Our results highlight the potential of sirtuin 2 inhibitors as broad-spectrum antivirals and set the stage for further understanding of how host epigenetic mechanisms impact the growth and spread of viral pathogens.

Roche et al.

Contact us to learn more about about our services for the testing of novel Hepatitis B virus therapeutic products in primary cells. HBV stock virus are also available for purchase for use in in vitro and in vivo assays.

The post ImQuest Publication Highlight: HBV Primary Human Hepatocyte Assays appeared first on ImQuest BioSciences.

ImQuest assisted with macr9molecular synthesis assays to support the the recent publication in Nature Chemical Biology. See the abstract below:

Abstract

The antimicrobial resistance crisis requires the introduction of novel antibiotics. The use of conventional broad-spectrum compounds selects for resistance in off-target pathogens and harms the microbiome. This is especially true for Mycobacterium tuberculosis, where treatment requires a 6-month course of antibiotics. Here we show that a novel antimicrobial from Photorhabdus noenieputensis, which we named evybactin, is a potent and selective antibiotic acting against M. tuberculosis. Evybactin targets DNA gyrase and binds to a site overlapping with synthetic thiophene poisons. Given the conserved nature of DNA gyrase, the observed selectivity against M. tuberculosis is puzzling. We found that evybactin is smuggled into the cell by a promiscuous transporter of hydrophilic compounds, BacA. Evybactin is the first, but likely not the only, antimicrobial compound found to employ this unusual mechanism of selectivity.

Imai et al.

Contact us to learn more about about our services for assessing antibacterial mechanism of action via macromolecular synthesis assays.

The post ImQuest Publication Highlights: Macromolecular Synthesis Assays appeared first on ImQuest BioSciences.

ImQuest assisted with antiviral range of action analysis and SARS-CoV2 screening which was recently presented at ICAR 2023. Click Here to view.

Contact us to learn more about about our broad range of antiviral testing services.

The post ImQuest Conference Highlight: Virus Panel Testing appeared first on ImQuest BioSciences.

ImQuest assisted antiviral testing for a recent publication in PLOS Pathogens. See the abstract below:

Abstract

EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). It is highly active against all RSV-A and B laboratory strains and clinical isolates tested in vitro in various cell lines and assays, with half-maximal effective concentrations (EC₅₀s) of 21, 23 and 64 nM against Long (A), M37 (A) and VR-955 (B) strains, respectively, in the primary human bronchial epithelial cells (HBECs). EDP-938 inhibits RSV at a post-entry replication step of the viral life cycle as confirmed by time-of-addition study, and the activity appears to be mediated by viral nucleoprotein (N). In vitro resistance studies suggest that EDP-938 presents a higher barrier to resistance compared to viral fusion or non-nucleoside L polymerase inhibitors with no cross-resistance observed. Combinations of EDP-938 with other classes of RSV inhibitors lead to synergistic antiviral activity in vitro. Finally, EDP-938 has also been shown to be efficacious in vivo in a non-human primate model of RSV infection

Rhodin et al.

Contact us to learn more about about our services for the testing of novel respiratory virus therapeutic products.

The post ImQuest Publication Highlight: Coronavirus and Antiviral Screening Capabilities appeared first on ImQuest BioSciences.

ImQuest published an article in AIDS Research and Human Retroviruses . See the abstract below:

Abstract

Dual compartment suppositories are being developed to prevent HIV and other sexually transmitted infections. Such products, for use in the rectum, the vagina, or both, could have a significant public health impact by decreasing global incidence of these diseases. In this study, 16 women each used two rheologically distinct suppositories in their vagina and rectum. User Sensory Perception and Experience (USPE) scales assessed sensory experiences during sexual activity to understand whether, and how, women perceive formulation properties in the vagina and rectum. Qualitative data from individual in-depth interviews captured women’s descriptions and comparisons of the experiences. Significant differences and large Cohen’s d effect sizes between vaginal and rectal experiences of suppository-A were found for three scales: Application (APP): Product Awareness, SEX: Initial Penetration; and SEX: Effortful. Qualitative data provided user experience details that credibly align with these score differences. Near significant differences and large effect sizes were found for two additional scales: SEX: Perceived Wetness with suppository-A and SEX: Messiness with suppository-B. In addition, other scale scores showed medium-to-large effect sizes that correspond to hypothesized sensations associated with biophysical properties of the suppositories. Statistical significance combined with large effect sizes and qualitative data accurately represent the hypothesized perceptibility of suppository properties and identifies performance characteristics relevant to acceptability and adherence; together these data provide discernment of factors that can guide the development of dual compartment products.

Guthrie et al.

Contact us to learn more about about our antiviral and STD prevention services and capabilities.

The post ImQuest Publication Highlight: HIV Prevention Product Development appeared first on ImQuest BioSciences.

Data produced by ImQuest’s team was recently highlighted in mBio (an ASM Journal). ImQuest BioSciences has a strong track record of working our clients to accelerate their research and development needs, and produce publication quality data as part of these services. As noted in Shahsavari et al, “Macromolecular incorporation assay was performed as a service by ImQuest Biosciences. E. coli W0153 strain” as a component of our services to identify compound mechanism of action. Various endpoints of bacterial biosynthetic pathways were evaluated, and were useful in identifying compound mechanism.

Antibacterial testing services are available at ImQuest for the evaluation of small molecules, natural products, immune modulators, biologics and therapeutic antibodies and provide necessary support from initial discovery, structure-activity relationship evaluation, lead identification and IND-directed preclinical development.

Contact us for more information.

The post Publication highlights ImQuest’s Microbiology Capabilities appeared first on ImQuest BioSciences.

Robert ‘Bobby’ Buckheit III has been recognized as one of Frederick’s Top 50 Professionals Under 40 by the Frederick County Office of Economic Development in partnership with Frederick Magazine. Bobby is Director of Sales & Business Development and a Manager of Immunology and Flow Cytometry Services at ImQuest BioSciences Inc. During the course of his six years at ImQuest, he has supported the development of contract research business in areas including, infectious disease, cancer, topical microbicides, formulation sciences, and immunology. He has continuously focused on furthering the company mission to provide clients with the highest level of technical and professional scientific expertise and capability by serving as a trusted advisor and indispensable partner throughout all stages of the developmental pathway.

The post Robert ‘Bobby’ Buckheit III has been recognized as one of Frederick’s Top 50 Professionals Under 40 appeared first on ImQuest BioSciences.

ImQuest assisted with studies to support the preprint of the following article. See the abstract below:

Abstract

FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS-CoV-2 replication. When combined with remdesivir, synergistic activity was seen (summary synergy score 24.7±9.56). FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections.

Fitzsimmons et al.

Contact us to learn more about about our services for the testing of novel respiratory virus therapeutic products.

The post ImQuest Publication Highlight: Respiratory Virus Capabilities appeared first on ImQuest BioSciences.